Clinical Pharmacokinetics and Pharmacodynamics of Selegiline
- 1 August 1997
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 33 (2) , 91-102
- https://doi.org/10.2165/00003088-199733020-00002
Abstract
Selegiline is a selective inhibitor of monoamine oxidase-B (MAO-B) at a dose of 10 mg/day and is given to patients with Parkinson’s disease as an adjunct to levodopa therapy. By inhibiting MAO-B,...Keywords
This publication has 28 references indexed in Scilit:
- An improved fluorimetric assay for brain monoamine oxidasePublished by Elsevier ,2002
- Selegiline Percutaneous Absorption in Various Species and Metabolism by Human SkinPharmaceutical Research, 1997
- PHARMACOKINETICS AND SAFETY OF A SELEGILINE TRANSDERMAL SYSTEM RELATIVE TO SINGLE-DOSE ORAL ADMINISTRATION IN THE ELDERLYClinical Journal of Sport Medicine, 1996
- An enzymatic assay for the MAO-B inhibitor selegiline in plasmaJournal of Pharmaceutical and Biomedical Analysis, 1994
- Atypical Metabolism of Deprenyl and Its Enantiomer, (S)-(+)-N,.alpha.-Dimethyl-N-Propynylphenethylamine, by Cytochrome P450 2D6Chemical Research in Toxicology, 1994
- Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapyJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1989
- R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.1987
- SELECTIVE ACETYLENIC ‘SUICIDE’ AND REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPES A AND BBritish Journal of Pharmacology, 1981
- Substrate- and inhibitor-related characteristics of human platelet monoamine oxidaseBiochemical Pharmacology, 1977
- Dopamine is a monoamine oxidase B substrate in manNature, 1977